These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20980259)

  • 1. Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S.
    Offman MN; Krol M; Silman I; Sussman JL; Futerman AH
    J Biol Chem; 2010 Dec; 285(53):42105-14. PubMed ID: 20980259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-ray and biochemical analysis of N370S mutant human acid β-glucosidase.
    Wei RR; Hughes H; Boucher S; Bird JJ; Guziewicz N; Van Patten SM; Qiu H; Pan CQ; Edmunds T
    J Biol Chem; 2011 Jan; 286(1):299-308. PubMed ID: 20980263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
    Atrian S; López-Viñas E; Gómez-Puertas P; Chabás A; Vilageliu L; Grinberg D
    Proteins; 2008 Feb; 70(3):882-91. PubMed ID: 17803231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C.
    Salvioli R; Tatti M; Scarpa S; Moavero SM; Ciaffoni F; Felicetti F; Kaneski CR; Brady RO; Vaccaro AM
    Biochem J; 2005 Aug; 390(Pt 1):95-103. PubMed ID: 15826241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.
    Alfonso P; Pampín S; Estrada J; Rodríguez-Rey JC; Giraldo P; Sancho J; Pocoví M
    Blood Cells Mol Dis; 2005; 35(2):268-76. PubMed ID: 16039881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
    Luan Z; Higaki K; Aguilar-Moncayo M; Ninomiya H; Ohno K; García-Moreno MI; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chembiochem; 2009 Nov; 10(17):2780-92. PubMed ID: 19830760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease.
    Thirumal Kumar D; Iyer S; Christy JP; Siva R; Tayubi IA; George Priya Doss C; Zayed H
    Adv Protein Chem Struct Biol; 2019; 114():315-339. PubMed ID: 30635084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease.
    Yu L; Ikeda K; Kato A; Adachi I; Godin G; Compain P; Martin O; Asano N
    Bioorg Med Chem; 2006 Dec; 14(23):7736-44. PubMed ID: 16919960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant.
    Babajani G; Tropak MB; Mahuran DJ; Kermode AR
    Mol Genet Metab; 2012 Jul; 106(3):323-9. PubMed ID: 22592100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of 3,4,5,6-tetrahydroxyazepanes to the acid-β-glucosidase active site: implications for pharmacological chaperone design for Gaucher disease.
    Orwig SD; Tan YL; Grimster NP; Yu Z; Powers ET; Kelly JW; Lieberman RL
    Biochemistry; 2011 Dec; 50(49):10647-57. PubMed ID: 22047104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective chaperone effect of aminocyclitol derivatives on G202R and other mutant glucocerebrosidases causing Gaucher disease.
    Serra-Vinardell J; Díaz L; Gutiérrez-de Terán H; Sánchez-Ollé G; Bujons J; Michelakakis H; Mavridou I; Aerts JM; Delgado A; Grinberg D; Vilageliu L; Casas J
    Int J Biochem Cell Biol; 2014 Sep; 54():245-54. PubMed ID: 25084554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms.
    Steet RA; Chung S; Wustman B; Powe A; Do H; Kornfeld SA
    Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13813-8. PubMed ID: 16945909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations.
    Liou B; Kazimierczuk A; Zhang M; Scott CR; Hegde RS; Grabowski GA
    J Biol Chem; 2006 Feb; 281(7):4242-53. PubMed ID: 16293621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase.
    Steet R; Chung S; Lee WS; Pine CW; Do H; Kornfeld S
    Biochem Pharmacol; 2007 May; 73(9):1376-83. PubMed ID: 17217920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.
    Sawkar AR; Adamski-Werner SL; Cheng WC; Wong CH; Beutler E; Zimmer KP; Kelly JW
    Chem Biol; 2005 Nov; 12(11):1235-44. PubMed ID: 16298303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.
    Lieberman RL; Wustman BA; Huertas P; Powe AC; Pine CW; Khanna R; Schlossmacher MG; Ringe D; Petsko GA
    Nat Chem Biol; 2007 Feb; 3(2):101-7. PubMed ID: 17187079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning.
    Romero R; Ramanathan A; Yuen T; Bhowmik D; Mathew M; Munshi LB; Javaid S; Bloch M; Lizneva D; Rahimova A; Khan A; Taneja C; Kim SM; Sun L; New MI; Haider S; Zaidi M
    Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5086-5095. PubMed ID: 30808805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.
    Sawkar AR; Cheng WC; Beutler E; Wong CH; Balch WE; Kelly JW
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15428-33. PubMed ID: 12434014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of N-substituted ε-hexonolactams as pharmacological chaperones for the treatment of N370S mutant Gaucher disease.
    Wang GN; Twigg G; Butters TD; Zhang S; Zhang L; Zhang LH; Ye XS
    Org Biomol Chem; 2012 Apr; 10(15):2923-7. PubMed ID: 22286559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of a molecular dynamics model with the X-ray structure of the N370S acid-beta-glucosidase mutant that causes Gaucher disease.
    Offman MN; Krol M; Rost B; Silman I; Sussman JL; Futerman AH
    Protein Eng Des Sel; 2011 Oct; 24(10):773-5. PubMed ID: 21724649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.